Abstracts Archive - Page 160 of 2607 - ACR Meeting Abstracts

Abstract Number: 0583 • ACR Convergence 2025
Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
Raquel Granados¹, Jesús Eduardo Martín Salazar², María Ángeles Puche-Larrubia³, Pedro Ortiz Buitrago⁴, María Dolores López-Montilla⁵, Jerusalén Calvo⁶, Rafaela Ortega-Castro⁷, Montserrat Romero-Gómez⁸, Alejandro Escudero-Contreras⁹, Nuria Barbarroja¹⁰ and Clementina López Medina¹¹, ¹Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain, ²Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁸Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ⁹Reina Sofia University Hospital/Maimonides Institute of Biomedical Research of Córdoba(IMIBIC)/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Previous studies have identified subgroups of patients with psoriatic arthritis (PsA) based on the severity of the disease [1,2]. However, no analysis to date…
Abstract Number: 0860 • ACR Convergence 2025
Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository
Maria Efthymiou¹, Ibrahim Tohidi-Esfahani², Veronica Venturelli¹, Maria Tektonidou³, Vittorio Pengo⁴, Diana Parades-Ruiz⁵, Ware Branch⁶, Maria Gerosa⁷, Cecilia Nalli⁸, Esther Rodriguez Almaraz⁹, Michelle Petri¹⁰, Ricard Cervera¹¹, Olga Amengual¹², Danieli Andrade¹³, Rohan Willis¹⁴, Maria Laura Bertolaccini¹⁵, Doruk Erkan¹⁶ and Hannah Cohen¹⁷, ¹University College London, London, United Kingdom, ²University of Sydney, Syndey, Australia, Sydney, Australia, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵Biobizkaia Health Research Institute, Barakaldo, Spain, Barakaldo, Spain, ⁶University of Utah Health Sciences Center, Salt Lake City, UT, ⁷University of Milan, Milano, Italy, ⁸ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁹Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Hospital Clinic Barcelona, Barcelona, Spain, ¹²Hokkaido University Graduate School of Medicine, Sapporo, Japan, Sapporo, Japan, ¹³University of Sao Paulo, São Paulo, São Paulo, Brazil, ¹⁴University of Texas Medical Branch, Galveston, TX, ¹⁵King's College London, London, United Kingdom, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Dysregulation in the protein C anticoagulant pathway, more specifically acquired resistance to activated protein C (APCr) and antibodies against protein C (anti-PC), has been…
Abstract Number: 0855 • ACR Convergence 2025
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Jane Salmon¹, Mimi Kim², Marta Guerra¹, Joseph Worden³, Carl Laskin⁴, Maria DeSancho⁵, Inna Landres⁵, Jason S. Knight⁶, Haley Slosberg¹, Margaret Minett¹ and Ware Branch⁷, ¹Hospital for Special Surgery, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Utah School of Medicine, Salt Lake City, ⁴University of Toronto, Toronto, ON, Canada, ⁵Weill Cornell Medicine, New York, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Utah Health Sciences Center, Salt Lake City, UT
Background/Purpose: The IMPACT trial (NCT03152058) showed that certolizumab appears effective in preventing placenta-mediated adverse pregnancy outcome (APO) in high-risk antiphospholipid syndrome (APS) patients. We have…
Abstract Number: 0571 • ACR Convergence 2025
Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Jaejoon Lee¹, A-Hyun Cho², Yu Jin Kim², Seulkee Lee³, Seonyoung Kang⁴, Hyungjin Kim⁵, Hoon-Suk Cha¹ and Hong-Hee Won², ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Biologics have transformed the management of axial spondyloarthritis (axSpA). Currently, it is challenging to identify patients who would benefit from early biologics, resulting in…
Abstract Number: 0590 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Vinod Chandran¹, Oliver FitzGerald², Philip J. Mease³, Lihi Eder⁴, Jose Scher⁵, Christopher Ritchlin⁶, Dafna D. Gladman⁷, Walter P Maksymowych⁸, Coryandar Gilvary⁹, Aditi Basu Bal⁹, Eleni Vritzali¹⁰ and Jinqi Liu⁹, ¹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ²UCD, Dublin ⁶, Dublin, Ireland, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵New York University School of Medicine, New York, NY, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Understanding how treatments affect disease-relevant biomarker expression is essential for advancing targeted therapies. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, has…
Abstract Number: 0593 • ACR Convergence 2025
Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus
Nina Oparina¹, Sarah Reid¹, Ahmne Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Øyvind Molberg³, Solbritt Rantapää-Dahlqvist⁵, Anna Rudin⁶, Chrisopher Sjöwall⁷, Anders Bengtsson⁸, Lars Rönnblom¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Linkoping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Clinical Sciences, Lund University,, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁷Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁸Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations. Genetic predisposition contributes significantly to its pathogenesis, and higher genetic load is…
Abstract Number: 0589 • ACR Convergence 2025
Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials
Sofia Ramiro¹, Anna Molto², Elena Nikiphorou³, Marcelo Pinheiro⁴, Jamie Urbanik⁵, Tianming Gao⁶, Shirley Chen⁷, Jayne Stigler⁸, Jessica A. Walsh⁹ and Lihi Eder¹⁰, ¹Leiden University Medical Center, Bunde, Netherlands, ²Assistance Publique Hôpitauxde Paris, Paris, France, ³King's College London, London, United Kingdom, ⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil, ⁵AbbVie, Grayslake, IL, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Somerset, NJ, ⁸AbbVie, Round Lake, IL, ⁹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: Evidence suggests that the treatment effectiveness of TNFis and IL-17is is higher in male (M) vs female (F) patients (pts) with axSpA.1,2 Data comparing…
Abstract Number: 0871 • ACR Convergence 2025
The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes
Vanya Sofia Villa Soto¹, Diego Orellana², Erin Reilly³, Chloe Heath², Alexandra Degraeve², Mohana Mukherjee², darren Dumlao², Rebecca Blank⁴, steven Yu², Noah Perlmutter², Judith Ashouri², Jose Scher⁵, andrew Patterson³, Peter Turnbaugh² and Renuka Nayak⁶, ¹University of California, San Francisco, San Francics, CA, ²University of California, San Francisco, San Francisco, CA, ³Pennsylvania State University, University Park, PA, ⁴NYU Langone Health, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Despite advances in targeted therapeutics, methotrexate (MTX) remains the first-line therapy in the treatment of rheumatoid arthritis (RA) and other inflammatory arthritides. However, more…
Abstract Number: 0846 • ACR Convergence 2025
A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification
Rezvan Parvizi¹, Zhiyun Gong², Natania Field³, Helen Jarnagin², Dillon Popovich², Monica Yang⁴, Kathleen Aren⁵, Mary Carns⁶, Isaac Goldberg⁷, Lorinda Chung⁸, Vivien Goh⁹, Zsuzsanna McMahan¹⁰, Tammara Wood¹¹, Dinesh Khanna¹², Monique Hinchcliff¹³ and Michael Whitfield¹⁴, ¹Dartmouth, lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Northwestern Memorial Hospital, Chicago, IL, ⁴UCSF, San Francisco, CA, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Wayne State University, Detroit, ⁸Stanford University, Stanford, CA, ⁹Northwestern, Chicago, ¹⁰UT Health Houston, Houston, TX, ¹¹Dartmouth, Hanover, NH, ¹²University of Michigan, Ann Arbor, MI, ¹³Yale School of Medicine, Westport, CT, ¹⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Mycophenolate Mofetil (MMF) is the most commonly prescribed immunosuppressive treatment for patients diagnosed with diffuse cutaneous systemic sclerosis (dcSSc). Here, we analyzed skin gene…
Abstract Number: 0599 • ACR Convergence 2025
Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Aakash V. Patel¹, Lingxiao Zhang², Emily S. Lau³, Baijun Zhou², Yuqing Zhang⁴, Hyon K. Choi⁵ and April Jorge⁶, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴Massachusetts General Hospital, Quincy, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Massachusetts General Hospital, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with up to a three-fold increased risk of myocardial infarction (MI) and stroke. Statins have well-established cardioprotective benefits…
Abstract Number: 0874 • ACR Convergence 2025
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Atul Deodhar¹, Ricardo Blanco², Arthur Kavanaugh³, Alice Gottlieb⁴, Laura Coates⁵, Christopher Ritchlin⁶, Alan Kivitz⁷, Xiaofeng Zeng⁸, Akimichi Morita⁹, Diamant Thaçi¹⁰, Stefan Varga¹¹, Kexuan Li¹¹, Ying-Ming Jou¹², Eleni Vritzali¹³ and Philip J. Mease¹⁴, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³University of California, San Diego, School of Medicine, San Diego, CA, ⁴Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁹Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol Myers Squibb, Boudry, Switzerland, ¹⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has an established clinical profile in moderate to severe plaque psoriasis with over…
Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Kimberly Lakin¹, John Spivack¹, Jessica Gordon¹, Dana Orange² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…
Abstract Number: 0588 • ACR Convergence 2025
The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
Casper Webers¹, AUGUSTA ORTOLAN², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: In axial spondyloarthritis (axSpA), peripheral musculoskeletal manifestations (peripheral arthritis, enthesitis, dactylitis) are common and contribute to the burden of disease. Our objective was to…
Abstract Number: 0561 • ACR Convergence 2025
Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Alan Kivitz¹, Linda Grinnell-Merrick², Tim Nguyen², Ariane Faucher³, Riley Taiji³, Francis Vekeman³ and Atul Singhal⁴, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³STATLOG, Inc, Montreal, QC, Canada, ⁴SouthWest Arthritis Research Group, Mesquite, TX
Background/Purpose: Since most approved biologics are administered subcutaneously, there is a need for alternate routes of delivery to treat patients with SpA. Secukinumab is an…
Abstract Number: 0609 • ACR Convergence 2025
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Eleni Papachristodoulou¹ and Vasileios Kyttaris², ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].